オプションチェーンは、Oruka Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Oruka Therapeuticsの市場センチメントを評価します。.

Oruka Therapeutics (NASDAQ:ORKA) 株価情報, オプションチェーン

Oruka Therapeutics

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Inc

William Blair initiated coverage on Butterfly Network Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NASDAQ">BFLY</a>), a digital health company that provides portable, semiconductor-based ultrasound technology <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">and intuitive software</a>.
The company reported a fourth-quarter adjusted loss of 5 cents per share, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 10 cents</a>.
Sales increased 35% year over year to $22.35 million, beating the consensus of $21.97 million, driven by the recently launched next-generation iQ3 probe&#8217;s higher selling price and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44038034/butterfly-network-reports-fourth-quarter-2024-financial-results" rel="noreferrer noopener">increased enterprise software revenue</a>.
Product revenue was $14.7 million, an increase of 45% versus the prior year period, driven by the 22% increase in units fulfilled year-over-year and the iQ3&#8217;s higher selling price.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44359442/protalix-biotherapeutics-says-with-debt-fully-repaid-its-well-positioned-to-execute-strategy-through-2025-and-beyond" rel="noreferrer noopener">Protalix BioTherapeutics Says With Debt Fully Repaid, It&#8217;s Well-Positioned To Execute Strategy Through 2025 And Beyond</a>
Butterfly Network expects 2025 sales of $96 million—$100 million, compared to a consensus of $97.80 million and an adjusted EBITDA loss of $37 million—$42 million.
&#8220;Butterfly is pioneering the digital ultrasound market, democratizing access to imaging and expanding its total addressable market (TAM),&#8221; William Blair writes. &#8220;The valuation ascribes only some success in the core point-of-care and hospital markets, but with execution on growth objectives, we believe shares can rise meaningfully.&#8221;
Analyst Andrew Brackmann <a href="https://www.benzinga.com/quote/BFLY/analyst-ratings" target="_blank" rel="noreferrer noopener">initiates with an Outperform</a> rating and notes that the company&#8217;s core business can grow roughly 20% over the next several years and likely closer to a low-to-mid-teens revenue compound annual rate between 2024 and 2030.
The William Blair analyst writes Butterfly&#8217;s homecare business has strong potential to boost revenue and expand market opportunities over the next 12 to 24 months.
While still in its early stages, the analyst sees it as a key growth driver that could become a multi-hundred-million-dollar business within five years. Despite this potential, the share price does not yet reflect these efforts.
Price Action: BFLY stock is up 2.05% at $2.74 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44358669/energy-vault-strengthens-australian-presence-with-220-million-acquisition-of-stoney-creek" target="_blank" rel="noreferrer noopener">Energy Vault Strengthens Australian Presence With Stoney Creek Deal: Details</a></li>
</ul>
Photo: Shutterstock

Analyst Color

News

Health Care

Initiation

Analyst Ratings

General

BFLY

Butterfly Network Is 'Pioneering Digital Ultrasound Market,' Analyst Says Undervalued Stock Could Rise With Growth Execution

Citigroup analyst Ronald Josey maintains trivago (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVG#NASDAQ">TRVG</a>) with a Neutral and raises the price target from $2.6 to $4.5.

Price Target

TRVG

Citigroup Maintains Neutral on trivago, Raises Price Target to $4.5

Citigroup analyst Kelly Crago maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Neutral and lowers the price target from $405 to $365.

ULTA

Citigroup Maintains Neutral on Ulta Beauty, Lowers Price Target to $365

CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) is flashing a bullish signal as it completes <a href="https://www.benzinga.com/topic/golden-cross">a Golden Cross</a> — an event where the 50-day simple moving average (SMA) rises above the 200-day SMA. 
With the stock up over 51% year to date and continuing to trade above key moving averages, technicals suggest further upside.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="618" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17133310/Screenshot-2025-03-17-at-5.08.30-PM.png" alt="" class="wp-image-827853" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17133310/Screenshot-2025-03-17-at-5.08.30-PM.png 618w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17133310/Screenshot-2025-03-17-at-5.08.30-PM-300x236.png 300w" sizes="(max-width: 618px) 100vw, 618px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Adding to investor enthusiasm, CVS's weight management program has delivered an average 15% weight loss for participants while cutting costs by 26%.
Read Also: <a href="https://www.benzinga.com//node/44346604">Allegations of Inflated Prescription Drug Costs Spark Employee Lawsuit Against JPMorgan</a>
<h2 class="wp-block-heading">CVS Stock Technicals Point To Strength</h2>
Several technical signals confirm CVS stock's strong uptrend:
<ul>
<li>Golden Cross Formation: The 50-day SMA ($57.86) has officially crossed above the 200-day SMA ($57.72), reinforcing a bullish outlook.</li>
<li>Momentum Stays Strong: CVS stock trades above its eight-day, 20-day and 50-day SMAs, confirming sustained buying pressure.</li>
<li>Moving Average Covergence/Divergence (MACD) Indicator: At 2.01, the MACD remains in bullish territory, signaling strong upward momentum.</li>
<li>Relative Strength Index (RSI): The RSI at 62.46, is nearing overbought territory, indicating that CVS stock remains in a strong trend, though some profit-taking could occur.</li>
</ul>
<h2 class="wp-block-heading">CVS Weight Loss Program Gains Traction</h2>
On the fundamental side, CVS reported that its Weight Management program led to an average 15% weight loss among participants and a 26% reduction in weight-loss drug costs. The program, which integrates GLP-1 medications with personalized nutrition plans, has been rolled out to 3.5 million members.
CVS stock has been riding this wave of positive news and strong technicals. The golden cross suggests continued bullish momentum, though with RSI creeping higher, short-term volatility could emerge. If buying pressure remains, CVS could see further gains in the coming weeks.
Related: 
<ul>
<li><a href="https://www.benzinga.com//node/44336874">CVS Weight Management Program Yields 15% Average Weight Loss, 26% Cost Saving Among Participants</a></li>
</ul>
Image: Shutterstock

Technicals

Signals

Tech

Trading Ideas

CVS Stock Flashes Golden Cross As Weight Loss Program Delivers Big Results

Citigroup analyst Paul Lejuez maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Neutral and lowers the price target from $11 to $8.

Citigroup Maintains Neutral on Kohl's, Lowers Price Target to $8

Citigroup analyst Paul Lejuez maintains Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Buy and lowers the price target from $65 to $60.

Citigroup Maintains Buy on Academy Sports, Lowers Price Target to $60

Small Cap Consumer Research analyst Eric Beder reiterated a <a href="https://www.benzinga.com/quote/LE/analyst-ratings">Buy rating </a>on the shares of Lands End Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) with a price forecast of $20.00 after reviewing the March catalog.
Lands&#8217; End&#8217;s March catalog highlights the start of the swim season, with over 40% of the 80-page catalog dedicated to swimwear and related items.
Themed &#8220;The Power of Pretty,&#8221; the catalog marks a significant step in developing a lifestyle-driven publication that offers complete looks across multiple categories.
Featuring everyday models, it allows customers to easily envision themselves in the brand's offerings. This approach targets a younger customer base and is expected to reduce heavy discounting on key items. 
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44356299/why-is-clothing-firm-guess-stock-surging-today">Why Is Clothing Firm Guess Stock Surging Today?</a>
The Lands&#8217; End catalog has transitioned from a sales-driven approach to one focused on emotional appeal. There is an increasing emphasis on multi-category styles that prioritize the overall look rather than pricing, said the analyst.
Starting with simple styles at the beginning of 2024, Lands&#8217; End has broadened its selection of bottoms to include denim and a new soft polish collection. This category now presents a significant growth opportunity for the brand.
According to the analyst, The emphasis on rain-ready outerwear has grown, with the lightweight Squall taking the lead, replacing the Wanderweight down styles from 2024. 
Meanwhile, footwear remains a standout, with popular Spring flats and slingbacks stealing the spotlight. Overall, the company's strategy is seen as strengthening its position in the market, asserted the analyst.
Price Action: LE shares traded higher by 2.55% at $11.05 at last check Monday.
Read Next: <a href="https://www.benzinga.com/general/health-care/25/03/44359600/hyperfine-nvidia-partner-to-make-brain-mris-more-affordable">Hyperfine, Nvidia Partner To Make Brain MRIs More Affordable</a>
Photo: Shutterstock

Reiteration

Lands' End Strengthens Catalog Strategy To Embrace Younger Audience, Says Analyst

Financial giants have made a conspicuous bearish move on Barrick Gold. Our analysis of options history for Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) revealed 20 unusual trades.
Delving into the details, we found 35% of traders were bullish, while 65% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $671,792, and 14 were calls, valued at $802,155.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $10.0 to $22.0 for Barrick Gold during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Barrick Gold options trades today is 5251.86 with a total volume of 9,542.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Barrick Gold's big money trades within a strike price range of $10.0 to $22.0 over the last 30 days.
<h3>Barrick Gold 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742235376_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$1.62</td>
<td>$1.58</td>
<td>$1.58</td>
<td>$19.00</td>
<td>$316.0K</td>
<td>5.8K</td>
<td align="right">3</td>
</tr>
<tr>
<td>GOLD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.8</td>
<td>$3.75</td>
<td>$3.8</td>
<td>$22.00</td>
<td>$155.8K</td>
<td>8.6K</td>
<td align="right">415</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$5.3</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$15.00</td>
<td>$141.9K</td>
<td>1.9K</td>
<td align="right">275</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$4.2</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$17.00</td>
<td>$122.5K</td>
<td>3.4K</td>
<td align="right">661</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$4.2</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$17.00</td>
<td>$108.6K</td>
<td>3.4K</td>
<td align="right">266</td>
</tr>
</tbody>
</table>

<h3>About Barrick Gold</h3>
Based in Toronto, Barrick Gold is one of the world's largest gold miners. In 2024, the firm produced nearly 3.9 million attributable ounces of gold and about 430 million pounds of copper. At year-end 2024, Barrick had about two decades of gold reserves along with significant copper reserves. After buying Randgold in 2019 and combining its Nevada mines in a joint venture with competitor Newmont later that year, it operates mines in 19 countries in the Americas, Africa, the Middle East, and Asia. The company also has growing copper exposure. Its potential Reko Diq project in Pakistan, if developed, could double copper production by the end of the decade.
After a thorough review of the options trading surrounding Barrick Gold, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Barrick Gold Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 12,398,193, the GOLD's price is up by 2.26%, now at $19.2. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 44 days.</li>
</ul>
<h3>What Analysts Are Saying About Barrick Gold</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $21.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a positive move, an analyst from UBS has upgraded their rating to Buy and adjusted the price target to $22. 
&#x2A; An analyst from Scotiabank persists with their Sector Perform rating on Barrick Gold, maintaining a target price of $20. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Barrick Gold options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

GOLD

This Is What Whales Are Betting On Barrick Gold

Citigroup analyst Scott Gruber maintains Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) with a Neutral and lowers the price target from $56 to $51.

Citigroup Maintains Neutral on Occidental Petroleum, Lowers Price Target to $51

Deep-pocketed investors have adopted a bearish approach towards Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HUM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 17 extraordinary options activities for Humana. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 29% leaning bullish and 47% bearish. Among these notable options, 11 are puts, totaling $1,294,783, and 6 are calls, amounting to $257,816.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $195.0 to $350.0 for Humana over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Humana options trades today is 621.09 with a total volume of 1,733.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Humana's big money trades within a strike price range of $195.0 to $350.0 over the last 30 days.
<h3>Humana Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742235370_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/28/25</td>
<td>$9.6</td>
<td>$8.1</td>
<td>$8.75</td>
<td>$255.00</td>
<td>$437.5K</td>
<td align="right">59</td>
<td align="right">507</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$37.1</td>
<td>$36.6</td>
<td>$36.98</td>
<td>$280.00</td>
<td>$287.2K</td>
<td align="right">229</td>
<td align="right">203</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$37.0</td>
<td>$36.7</td>
<td>$36.88</td>
<td>$280.00</td>
<td>$162.4K</td>
<td align="right">229</td>
<td align="right">105</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$23.0</td>
<td>$22.5</td>
<td>$22.5</td>
<td>$260.00</td>
<td>$65.2K</td>
<td align="right">706</td>
<td align="right">29</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$38.0</td>
<td>$37.6</td>
<td>$37.8</td>
<td>$280.00</td>
<td>$60.4K</td>
<td align="right">229</td>
<td align="right">25</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Current Position of Humana</h3>
<ul>
<li>Currently trading with a volume of 481,880, the HUM's price is down by 0.0%, now at $252.88. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 37 days.</li>
</ul>
<h3>Expert Opinions on Humana</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $256.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Neutral rating on Humana with a target price of $256. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Humana, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Spotlight on Humana: Analyzing the Surge in Options Activity

Financial giants have made a conspicuous bullish move on Philip Morris Intl. Our analysis of options history for Philip Morris Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) revealed 14 unusual trades.
Delving into the details, we found 42% of traders were bullish, while 42% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $56,700, and 12 were calls, valued at $2,229,453.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $125.0 and $155.0 for Philip Morris Intl, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Philip Morris Intl's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Philip Morris Intl's significant trades, within a strike price range of $125.0 to $155.0, over the past month.
<h3>Philip Morris Intl Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742235365_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$18.4</td>
<td>$17.9</td>
<td>$18.4</td>
<td>$140.00</td>
<td>$1.1M</td>
<td>546</td>
<td>600</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$10.2</td>
<td>$9.9</td>
<td>$9.98</td>
<td>$155.00</td>
<td>$227.9K</td>
<td>1.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$7.5</td>
<td>$7.4</td>
<td>$7.4</td>
<td>$155.00</td>
<td>$198.3K</td>
<td>3.0K</td>
<td>515</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$10.4</td>
<td>$10.1</td>
<td>$10.2</td>
<td>$155.00</td>
<td>$196.8K</td>
<td>1.0K</td>
<td>1.1K</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$10.4</td>
<td>$10.2</td>
<td>$10.2</td>
<td>$155.00</td>
<td>$181.5K</td>
<td>1.0K</td>
<td>1.4K</td>
</tr>
</tbody>
</table>

<h3>About Philip Morris Intl</h3>
Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heatsticks, vapes, and oral nicotine offerings primarily outside of the US. With the 2023 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI has not only diversified away from smokeable products but also gained a toehold into the US to sell its iQOS heated tobacco product.
Having examined the options trading patterns of Philip Morris Intl, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Philip Morris Intl's Current Market Status</h3>
<ul>
<li>With a trading volume of 3,589,929, the price of PM is up by 2.19%, reaching $155.21.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 37 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Philip Morris Intl</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $167.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Philip Morris Intl with a target price of $175. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Philip Morris Intl, which currently sits at a price target of $160. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Philip Morris Intl options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Unpacking the Latest Options Trading Trends in Philip Morris Intl

Citigroup analyst Scott Gruber maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Buy and raises the price target from $51 to $60.

Citigroup Maintains Buy on EQT, Raises Price Target to $60

Citigroup analyst Scott Gruber maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Neutral and lowers the price target from $134 to $125.

Citigroup Maintains Neutral on EOG Resources, Lowers Price Target to $125

<a href="https://www.cnn.com/2025/03/17/business/us-steel-nippon-trump-cfius/index.html" title="https://www.cnn.com/2025/03/17/business/us-steel-nippon-trump-cfius/index.html">https://www.cnn.com/2025/03/17/business/us-steel-nippon-trump-cfius/index.html</a>

Politics

'Trump signals that he may let US Steel make a deal with Nippon after Biden blocked it' -CNN Report

Citigroup analyst Scott Gruber maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Neutral and lowers the price target from $195 to $157.

FANG

Citigroup Maintains Neutral on Diamondback Energy, Lowers Price Target to $157

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 400 points on Monday.
The Dow traded up 0.97% to 41,888.57 while the NASDAQ climbed 0.33% to 17,812.14. The S&amp;P 500 also rose, gaining, 0.72% to 5,679.43.
Check This Out: <a href="https://www.benzinga.com/25/03/44324575/top-3-industrials-stocks-that-may-rocket-higher-this-month">Top 3 Industrials Stocks That May Rocket Higher This Month</a>
Leading and Lagging Sectors Energy shares jumped by 1.9% on Monday.
In trading on Monday, consumer discretionary shares fell by 0.3%.
Top Headline
U.S. retail sales rose 0.2% month-over-month in February following a revised 1.2% decline in January but down from market expectations of a 0.6% rise.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) shares shot up 28% to $12.45 after the company announced it received a non-binding proposal from WHP Global to acquire the company for $13 per share in cash.</li>
<li>Shares of Qifu Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>)got a boost, surging 11% to $48.04 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Baidu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) shares were also up, gaining 9% to $102.50 after the company announced the launch of ERNIE 4.5 and deep-thinking model ERNIE X1.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Solaris Energy Infrastructure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) shares dropped 17% to $20.40 after Morpheus Research issued a report.</li>
<li>Shares of Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) were down 15% to $4.2650.</li>
<li>Gorilla Technology Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) was down, falling 14% to $29.01 after Citron Research made comments criticizing the company on social media.</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $67.69 while gold traded up 0.2% at $3,007.00.
Silver traded down 0.2% to $34.355 on Monday, while copper rose 1.6% to $4.9755.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.79%, Germany's DAX 40 jumped 0.73% and France's CAC 40 gained 0.57%. Spain's IBEX 35 Index rose 1.09%, while London's FTSE 100 rose 0.56%.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei gaining 0.93%, China's Shanghai Composite Index gaining 0.19%, Hong Kong's Hang Seng Index surging 0.77% and India's BSE Sensex gaining 0.46%.
Economics
<ul>
<li>U.S. retail sales rose 0.2% month-over-month in February following a revised 1.2% decline in January but down from market expectations of a 0.6% rise.</li>
<li>The NY Empire State Manufacturing Index declined 26 points to -20.0 in March, recording the lowest reading since May 2023.</li>
<li>The NAHB/Wells Fargo Housing Market Index fell to 39 in March versus a reading of 42 in February.</li>
<li>U.S. business inventories increased 0.3% month-over-month in January following a 0.2% drop in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44325485/wall-streets-most-accurate-analysts-spotlight-on-3-real-estate-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields</a></li>
</ul>

Eurozone

Commodities

Intraday Update

ADTX

BIDU

GRRR

QFIN

Dow Jumps 400 Points; US Retail Sales Increase Less Than Expected

Citigroup analyst Scott Gruber maintains Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) with a Buy and lowers the price target from $48 to $46.

Citigroup Maintains Buy on Devon Energy, Lowers Price Target to $46

Prominent crypto chart analyst Ali Martinez has shared insights into his trading strategy, demonstrating how disciplined execution and risk-reward balance have helped him generate significant profits <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44260478/i-lost-everything-trader-turns-0-into-5-million-loses-it-all-with-meme-coins-that-were-sup">despite occasional setbacks</a>.
What Happened: In an X <a href="https://x.com/ali_charts/status/1901484638876389413">post</a> on Monday, Martinez emphasized that losses are an unavoidable part of trading but managing them effectively ensures that winning trades outweigh the losses over time. 
He highlighted that successful trading is about maintaining discipline and a strong risk-reward strategy.
Over the past two weeks, despite taking two losses, Martinez&#8217;s four winning trades resulted in a 242.53% gain, all achieved without leverage. His top performer during this period was Virtuals Protocol (CRYPTO: VIRTUAL), delivering a 30.4% profit from a March 4 entry at an average price of $0.934.
Martinez also holds Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) in his portfolio. 
SHIB saw a 0.05% gain from a single trade on Jan. 6.
DOGE had mixed results—his Jan. 3 trade resulted in an 8.6% loss, and his Jan. 13 trade dropped another 1.7%. 
However, later trades on Jan. 31 and Feb. 22 turned profitable, yielding 8% and 18% returns, respectively.
XRP- A Consistent Performer
Martinez's futures trading strategy has consistently favored XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>). 
His first XRP trade on Dec. 30 at an average entry price of $2.20 yielded a 7.5% gain, with a target set at $10.34 and a stop-loss at $1.789. 
His Jan.11 trade returned 25%, while trades on Feb. 14 and Feb. 24 delivered 8% and 19% gains, respectively.
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44260478/i-lost-everything-trader-turns-0-into-5-million-loses-it-all-with-meme-coins-that-were-supposed-to-become-the-next-dogecoin-shiba-inu">&#8216;I Lost Everything&#8217;—Trader Turns 0 Into $5 Million, Loses It All With Meme Coins That Were Supposed To Become The Next Dogecoin, Shiba Inu</a>
What's Next: In another X <a href="https://x.com/ali_charts/status/1901531446814376432">post</a>, Martinez identified a head-and-shoulders pattern forming on the weekly XRP chart, emphasizing that holding the $2 support level will be crucial for XRP's next move.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> is shaping up a head-and-shoulders on the weekly chart. It spotlights the $2 support. Holding it is crucial. <a href="https://t.co/icoVFwbBB9">pic.twitter.com/icoVFwbBB9</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1901531446814376432?ref_src=twsrc%5Etfw">March 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44348215/bitcoin-whale-takes-332-million-short-position-heres-where-it-gets-liquidated">Bitcoin Whale Takes $332 Million Short Position, Here&#8217;s Where It Gets Liquidated</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$SHIB

$XRP

XRP Delivering Steady Gains For Prominent Trader—Can Dogecoin, Shiba Inu Keep Up?

Citigroup analyst Scott Gruber maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Neutral and lowers the price target from $24 to $20.

Citigroup Maintains Neutral on APA, Lowers Price Target to $20

The S&amp;P 500 had another bloody day on Thursday, once again dropping more than 1% and officially entering correction territory. A correction is typically defined as a 10% drop from all-time highs and while they're common even in bull market years, the speed of the most recent drop has investors jittery.
With tariff uncertainty and economic slowdown fears looming large, defensive sectors are outperforming. Some of 2024's biggest winners have taken some heavy hits to start 2025.
Markets could undoubtedly fall further from here, but corrections are often ideal times to search for good companies trading at discounts. Some names that have been hammered hardest recently are reaching oversold levels and many of them still have solid fundamentals and upside potential.
Here are five oversold stocks that look close to a turning point.
Today, we'll use the Relative Strength Index (RSI) to find five stocks that have been oversold in the market drop of these last few weeks.
<h2 class="wp-block-heading">First Citizens BancShares Inc. </h2>
First Citizens Bank and Trust Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) was a relatively obscure large-cap regional bank holding company until about two years ago, when the firm acquired the floundering Silicon Valley Bank during the banking crisis of 2023. The stock plummeted to $500 per share in March 2023 while the crisis loomed over the sector, but the government bailed out the troubled bank and its assets were sold off. First Citizens acquired SVB's commercial banking business at the end of March and FCNCA shares rallied nearly 200% in just three months following the acquisition.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXd3ULK-TF-W17WlDuTNwPRzPUwN0VReqCqBLL8XiceRB-ZjApRK_JBBlZTL6A5Z3EIPm1K7hbbpQQksBmhZVR_FpeiJUO_Xojj_yzmKjHYZIEHPSwv8TMrX4ewkGQGkWU4j8jIv?key=t8rk1H-mqlcYEfVzNqwDMcYd" alt="" /></figure>
The stock set a new all-time high of $2410 in January 2025 before pulling back in the recent market correction. However, the company is still well-positioned and the current 25% drawdown could present a buying opportunity. The company has strong margins for a regional banking group with an operating margin of 25.3% and profit margins of 18.2%.
EPS growth in 2025 is expected to decline due to accumulating expenses and debt, but the company projects 14% EPS growth in 2026 and the stock is trading at just nine times forward earnings. FCNCA also has a 90.09 Quality score on Benzinga Edge rankings. The RSI has shot up to 56 following a dip below the oversold threshold of 30, signaling a potential reversal.
<h2 class="wp-block-heading">Amazon Inc. </h2>
Investors were able to purchase Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares for less than $90 in late 2022. Those willing to take the leap were rewarded with gains of nearly 300% in just two-and-a-half years. While buying stocks in the heart of a bear market is challenging, Amazon withstood the Dot Com Bubble, the Great Financial Crisis, the COVID-19 pandemic and the 2022 bear market &#8211; rebounding to new all-time highs in the aftermath of each event. Today, the stock is down 18% from all-time highs, which hardly qualifies as a calamity. However, quality stocks don't go on sale very often, which could allow buyers to accumulate more shares.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXdqQwmyhZdtFKpn17hYN-HdQNvAkydaBJdnHo9mc1DrLRH886szOx39JbtR0uHPOV6T_ym_kurpbMoyRiSxtXcTW-dY400LA7fHS6vsfs-7vyCtDaa71v4l3Tz8DXeMWEX0C1jL_A?key=t8rk1H-mqlcYEfVzNqwDMcYd" alt="" /></figure>
AMZN shares have been triggering oversold readings on the RSI since February, but the stock continued to grind lower through the end of the month and into March. The most recent oversold signal was triggered on March 11 and the RSI quickly jumped back above 50.
The company&#8217;s share price has yet to follow this move, although a double bottom pattern appears to be forming, which would reinforce the trend reversal signal from the RSI. Amazon has a 73.21 Momentum score and 82.1 Quality score from Benzinga Edge and trades at 35 times earnings, which is the lowest P/E for the stock since the pandemic.
<h2 class="wp-block-heading">Evercore Inc. </h2>
Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>) was expected to be one of the big winners under the new Trump administration as they specialize in mergers, acquisitions and restructuring advisory services. But the new administration has left many of the tight Biden-era FTC rules in place and Evercore's stock has faded in 2025. After hitting an all-time high of $324 following the 2024 US election, the stock had dropped below $190 by March &#8211; a more than 40% decline. However, the Evercore selloff may be reaching an end as the RSI triggered an oversold signal on March 11.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXc3SAk8V45FuO71djvIj6Oj3hPyTstJmIWqmwU0PhsN9OAbZK4oVLyutMtyLtB7EHsUPjYZm1q_9RYob7lQDWL97oVZ8J2tKu2JLciU2TII15wow0LGPkDB09s5uBLpk5PP1RE00Q?key=t8rk1H-mqlcYEfVzNqwDMcYd" alt="" /></figure>
Evercore's underlying business remains strong despite the lack of M&amp;A activity. The company has a 12.6% profit margin and projects EPS growth of over 37% in 2025. The valuation is also enticing, with a Forward P/E of 10.89 and a Price to Free-Cash-Flow rate of 8.47. Evercore's Benzinga Edge scores are excellent, too: 90.41 for Quality and 84.00 for Growth.
<h2 class="wp-block-heading">Hub Group Inc. </h2>
Transportation stocks have been crushed to start 2025 and Hub Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBG#NASDAQ">HUBG</a>) has been no exception. After closing at an all-time high of $53.21 on November 25, the rail and trucking firm has lost 30% in the last three months, significantly underperforming major market indices. The stock has also triggered three oversold signals on the RSI, most recently on March 13.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXd6kB4UJwfjU4O3e_CWIbZeHBMNRqeNaWLt6wimbAcyyuBzyJYT1t_JszbDCvc0qE1pneXrJcgMbz_loCRyLLSy1CBVjsSwVW4ciM6qvwqzJgPB6tnc9l5J7N5kUKcQ5s7opUBr0Q?key=t8rk1H-mqlcYEfVzNqwDMcYd" alt="" /></figure>
Hub Group is a good rebound candidate from here because the company has solid fundamentals and very little debt in what's traditionally a low-margin business. Hub Group's 0.31 debt/equity ratio is far lower than that of competitors like UPS, FedEx and J.B. Hunt and its stock trades at just 13 times forward earnings. Hub Group expects EPS growth of 14% in 2025 and 29% in 2026, a promising outlook. If the company can hit those earnings projections, the stock's current price could look like quite a bargain.
<h2 class="wp-block-heading">Abercrombie and Fitch Co. </h2>
Abercrombie and Fitch's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) turnaround was a big story in markets as the stock rallied from $23 in May 2023 to $197 in June 2024. The parabolic stock move wasn't just a short squeeze either, as the company has grown EPS by 78% over the last five years thanks to sales growth and margin expansion. However, the stock is currently in a brutal drawdown, losing more than 60% of its value since that June 2024 all-time high. Is the bottom finally settling? The RSI is hinting that this may be the case.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXfZxTvj5sPG2RF4N1xq9Z_kz1lDaMmLzBPbkZTuKBBosVT5nz6rKicLjta9TJDpAhIqQTS74HyAzno8qYPhYXU6EU-rg2v9iYlS8XSky7kNhggqbrtUCAoqXt9T1xT0jrxo0ghFzA?key=t8rk1H-mqlcYEfVzNqwDMcYd" alt="" /></figure>
False oversold signals from the RSI have been common during ANF's decline, but the most recent one quickly reversed and headed back over 50, potentially signaling a trend reversal. ANF has strong underlying metrics, like a profit margin of 11.44%, easily surpassing competitors like American Eagle, Urban Outfitters and The Gap. The stock trades at just 6.7 times forward earnings and has earned Benzinga Edge scores of 91.86 in Growth and 83.77 in Value.
<h2 class="wp-block-heading">Live On Wednesday: How To Trade The Fed's Market-Moving Decision</h2>
 The March 19-20 Fed meeting is set to shake the markets. Will Powell signal rate cuts or hold firm? Either way, volatility is coming and traders who prepare now will have the edge. Join Nic Chahine on <a href="https://events2.benzinga.com/nic-chahine-webinar-wed-mar19-2025-registration">Wednesday, March 19</a>, at 6 PM ET to learn the exact stocks and options setups he's watching before, during and after the Fed's decision. Reserve your seat now.
Photo: Shutterstock

Comments

Oruka Therapeutics

Oruka Therapeutics (ORKA) オプション

Loading...

ニュース

パートナーシップ

ベンジンガ・グローバル